<DOC>
	<DOCNO>NCT01884428</DOCNO>
	<brief_summary>study ass maximum tolerate dose ( MTD ) , safety , tolerability activity IGEV ( Ifosfamide , Gemcitabine , Vinorelbine , Prednisolone ) + Panobinostat new combination order determine recommend phase II dose</brief_summary>
	<brief_title>Study Combination PIGEV Before Autologous Stem Cell Transplant Patients With Hodgkin 's Lymphoma</brief_title>
	<detailed_description>Patients receive 4 p-IGEV course repeat every 3 week absence unacceptable toxicity , whenever objective response observe disease evaluation perform II cycle . Eligible patient accrue cohort 3 patient dose level dose escalation perform follow standard 3+3 rule . Three patient treat dose-level , start level 1 , one cycle : dose-limiting toxicity ( DLTs ) record first cycle , treatment continue patient study completion unacceptable toxicity three new patient treat next dose level . However , one 3 patient develop DLT , dose-level administer three additional patient one cycle . If one additional patient experience DLT , dose escalation continue . If one 3 6 patient develop DLT first cycle cohort , MTD reach . Six patient treat low dose order obtain information optimal dose phase II trial characterize pharmacokinetic profile combination . If DLT find level 1 ( 20 mg ) , 3 patient treat dose -1 ( 10 mg ) . If 1 patient experience toxicity , 3 patient treat assess information pharmacokinetic profile safety .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Diagnosis relapse refractory classical HL Measurable disease One two prior systemic line treatment PS ( ECOG ) 02 Absence bone marrow infiltration Adequate laboratory value bone marrow , liver renal functionality prior concurrent treatment DAC inhibitor include panobinostat valproic acid therapy medical condition study within 5 day prior first panobinostat treatment previous autologous hematopoietic stem cell transplant concurrent therapy intend treat primary cancer include chemotherapy , investigational biologic agent antitumor agent impaired cardiac function unstable AF know history HIV seropositivity , chronic hepatitis , active viral infection Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption panobinostat ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , obstruction , stomach and/or small bowel resection ) pregnant breast feeding woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Hodgkin</keyword>
	<keyword>Lymphoma</keyword>
</DOC>